Table 1.
Patient demographic, clinicopathological, germline and tumor genotype data
| Variable | N (%) for categorical variables |
|---|---|
| Age (N: 194) | |
| Mean ± SD | 51.4±12.6 |
| Median | 51 |
| Min-max | 21-77 |
| Menopausal status | |
| Postmenopausal | 99 (51.0%) |
| Premenopausal | 95 (49.0%) |
| Tumor size | |
| ≤2 cm | 74 (38.1%) |
| >2 cm | 118 (60.9%) |
| Missing/not applicable | 2 (1.0%) |
| Positive nodes | |
| ≥4 | 42 (21.7%) |
| 0-3 | 149 (76.8%) |
| Missing/not applicable | 3 (1.5%) |
| Adjuvant hormonotherapy | |
| NO | 165 (85.0%) |
| YES | 29 (15.0%) |
| Adjuvant radiotherapy | |
| NO | 54 (27.8%) |
| YES | 140 (72.2%) |
| Histological grade | |
| I or II | 28 (14.4%) |
| III | 166 (85.6%) |
| Histological type | |
| Lobular | 6 (3.1%) |
| Medullary | 11 (5.7%) |
| Metaplastic | 5 (2.5%) |
| Ductal, no special type | 159 (82.0%) |
| Other | 13 (6.7%) |
| TNBC upon central testing | |
| NO | 27 (13.9%) |
| YES | 167 (86.1%) |
| Ki67 (%; N: 177) | |
| Mean ± SD | 53.9±31.7 |
| Median | 56 |
| Min-max | 0-100 |
| Basal^ | |
| YES | 160 (82.5%) |
| NO | 26 (13.4%) |
| Missing | 8 (4.1%) |
| TILs density % (N: 188) | |
| Mean ± SD | 22.2±21.0 |
| VMedian | 15 |
| Min-max | 0-85 |
| Disease-free survival data | |
| N patients | 194 |
| Median follow up (months) | 59 |
| Relapse, N (%) | 54 (27.8%) |
| Event free at 3 years, N (%) | 144 (74.2%) |
^
EGFR and/or CK5 IHC positive.